CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 77.3 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder. Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Handel Vir Biotechnology VIR

VirBiotechnology live diagram

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

VirBiotechnology news

Seneste nyheder

Vis mere
Ghko B 2025 Jun 05, 16:00

Trump-Musk Relationship Collapses: Tesla Stock Drops 10%

Stocks
Ghko B 2025 Jun 04, 16:00

SOFI Stock Analysis: What is the 5-year forecast for SoFi?

Stocks
Ghko B 2025 Jun 04, 16:00

VOO Performance Analysis: Is Vanguard S&P 500 ETF good to invest in?

ETFs
Ghko B 2025 Jun 04, 16:00

Intel Stock Is Trending Now: What to Know about Intel Corporation (INTC)?

Stocks
Tommy Yap 2025 Jun 04, 16:00

Morning Note: ECB Rate Cut Expected; Canada PMI in Focus; EUR/USD, USD/CAD

Morning Note Forex CAD
Tommy Yap 2025 Jun 04, 16:00

Morning Note: ECB Rate Cut Expected; Broadcom Earnings; Oil Falls on Supply

Morning Note Tech Commodities
Frances Wang 2025 Jun 03, 16:00

AI Stock Analysis: PLTR Hits Record High as Government Deals Fuel Momentum

Stocks
Frances Wang 2025 Jun 03, 16:00

ACHR Stock Analysis: What’s Driving Archer Aviation's Market Performance?

Stocks

Info

Spread

0.05

Spread (%)

0.9690 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market lukket

Fredag

13:31 - 19:59

Mandag

13:31-19:59

Tirsdag

13:31-19:59

Onsdag

13:31-19:59

Torsdag

13:31-19:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

729896640

Aktier udestående

138238000

Indtjeningsdato (Næste)

0000-00-00

Udbytteprocent

Ex-udbyttedato

Forventet årlig udbyttesats

0

Forventet årlig udbytteprocent

0

EPS

-4.27

Få mere at vide om dette instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre
Relaterede instrumenter

latest_education_articles

Vis mere
Trustpilot